Back to Peptides

GHRP-2

Growth Factors & Muscle Building

GHRP-2 is a potent growth hormone secretagogue that stimulates the natural release of GH via the ghrelin receptor. It has been evaluated in preclinical and limited human research for its endocrine and appetite-regulating effects. It supports GH-IGF-1 axis activation with minimal prolactin or cortisol impact at moderate doses.

Reconstitute
3 mL BAC + 10mg vial
33 mcg/unit
Daily Range
100–300 mcg Subcutaneous (SQ)
1-2 times daily (pre-meal or pre-sleep)
Standard Dose
200 mcg
Cycle
4–8 weeks
then reassess
GHRP-2growth hormoneghrelin mimeticsecretagoguepeptide therapy

Dosing & Reconstitution Guide

In animal models, GHRP-2 is often used at 100–200 μg/kg via subcutaneous injection. Limited human studies have used 100–300 μg doses for investigational purposes only. It is not FDA-approved for clinical use.

Standard / Gradual Approach

10mg Vialstandard
PhaseDoseVolume
Weeks 1–2100 mcg3 units (0.03 mL)
Weeks 3–4150 mcg4.5 units (0.045 mL)
Weeks 5–8200 mcg6 units (0.06 mL)
Weeks 9–12250–300 mcg7.5–9 units (0.075–0.09 mL)

Standard / Gradual Approach

5mg Vialstandard
PhaseDoseVolume
Weeks 1–2100 mcg6 units (0.06 mL)
Weeks 3–4150 mcg9 units (0.09 mL)
Weeks 5–8200 mcg12 units (0.12 mL)
Weeks 9–12200 mcg12 units (0.12 mL)
Weeks 13–16200 mcg12 units (0.12 mL)

Protocol Summary

Subcutaneous (SQ): 1-2 times daily (pre-meal or pre-sleep) · Dose range 100–300 mcg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending

Frequency & Cycling

SubQ Injection

Use 1–2x daily for 6–12 weeks, followed by 2–4 week break to reset receptor sensitivity. Combine with GH-releasing peptides like CJC-1295 for best results.

🧪 Quick Start

Vial Size
10 mg
BAC Water
3 mL
Concentration
3.33 mcg/unit
Starting Dose
100 mcg (3 units (0.03 mL))
Maintenance Dose
250–300 mcg (7.5–9 units (0.075–0.09 mL))

Potential Benefits & Use Cases

GHRP-2 is a research-use-only compound. It is not approved for human or veterinary application.
Supports pulsatile GH release and may increase IGF-1 levels with consistent use (human trial)
May support improvements in body composition, recovery, and sleep quality (preclinical)
Demonstrates cardiovascular protection — improves LV function and reduces oxidative stress in heart failure models (preclinical)
Supports immune system via thymus gland rejuvenation and T-cell maturation (preclinical)
Clinical data Strong preclinical Limited data

Mechanism of Action

→Binds to ghrelin receptor (GHS-R1a) on pituitary somatotrophs
→Promotes endogenous pulsatile GH secretion
→Enhances IGF-1 production downstream of GH
→Activates hunger and energy regulation via hypothalamic stimulation

Lifestyle & Optimization

timing

Inject on empty stomach (2–3 hours post-meal).

diet

Protein-forward diet.

exercise

Resistance and aerobic activity.

sleep

Prioritize sleep and stress management.

Peptide Research & Preclinical Studies

Evidence-Based Research Findings

Study TitleType
Wikipedia — Pralmorelin (GHRP-2)Reference
PubMed — Effects of GHRP-2 and hexarelin on GHReference
PubMed — Diagnostic studies with GHRP-2 in childrenReference
PMC — Growth Hormone Secretagogue TreatmentReference
Endocrine Reviews — Growth hormone secretion during sleepReference
PubMed — Five-day subcutaneous GHRP-2 treatmentReference
Asian-Australas J. Anim. Sci. — Twice-daily GHRP-2 in swineReference

Side Effects & Safety

Common Side Effects

• Transient appetite increase (ghrelin receptor activation)
• Transient cortisol and prolactin elevation
• Receptor desensitization (tachyphylaxis) with continuous daily use; cycling recommended

🧮 Dose Calculator

Concentration
33.3
mcg/unit
Draw Volume
15
units (0.150 mL)
For a 500 mcg dose, draw 15 units on a U-100 insulin syringe
🧬

Bioavailability & Absorption

SubQ Injection
High for peptide-based GH stimulation; commonly used via this route
Oral Administration
Poor due to enzymatic degradation and low systemic absorption
Half-Life
Approx. 30 minutes
Degradation
Metabolized hepatically and renally
Tissue Specificity
Targets pituitary gland and hypothalamus
⚗️

Peptide Details

Molecular Weight
817
Formula
C45H55N9O6
Sequence
D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
⚖️

Legal Status & Regulatory

RegionStatus
FDANot Approved
EUNot Approved
AustraliaNot Approved
CanadaNot Approved

Storage Instructions

Lyophilized (Powder)
freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 28 days
Reconstituted (Mixed)
Refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days. Avoid freeze–thaw; aliquot if needed